FDA has approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute shows that most people continue to believe that pancreatic disease affects only elderly people—and that there is nothing they can do to...
